Development of cytarabine prodrugs and delivery systems for leukemia treatment

Phosphoramidates of 2′-β-d-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism

(2010) Youcef Mehellou et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Cationic lipid-mediated nucleic acid delivery: beyond being cationic

(2010) N. Madhusudhana Rao   CHEMISTRY AND PHYSICS OF LIPIDS

Current and emerging therapies for acute myeloid leukemia

(2010) Tadeusz Robak et al.   CLINICAL THERAPEUTICS

Induction therapy in acute myeloid leukemia: intensifying and targeting the approach

(2010) Hugo F Fernandez et al.   CURRENT OPINION IN HEMATOLOGY

Strategy for effective brain drug delivery

(2010) M. Intakhab Alam et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Liposomal cancer therapy: exploiting tumor characteristics

(2010) Thomas Kaasgaard et al.   Expert Opinion on Drug Delivery

Emerging drugs for chronic myeloid leukemia

(2010) Daniela Cilloni et al.   EXPERT OPINION ON EMERGING DRUGS

Emerging therapy for the treatment of acute lymphoblastic leukemia

(2010) Amber Fullmer et al.   EXPERT OPINION ON EMERGING DRUGS

Pharmacogenomics of pediatric acute lymphoblastic leukemia

(2010) Nathan D Meeker et al.   EXPERT OPINION ON PHARMACOTHERAPY

Clinical applications of PET and PET/CT in pediatric malignancies

(2010) Rakesh Kumar et al.   Expert Review of Anticancer Therapy

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts

(2010) Wah-Seng Lim et al.   LEUKEMIA RESEARCH

The molecular pathology of cancer

(2010) Timothy J. R. Harris et al.   Nature Reviews Clinical Oncology

Targeting Anticancer Drugs to Tumor Vasculature Using Cationic Liposomes

(2010) Amr S. Abu Lila et al.   PHARMACEUTICAL RESEARCH

Current issues in research on structure–property relationships in polymer nanocomposites

(2010) J. Jancar et al.   POLYMER

Novel Drug Delivery Systems for Sustained and Targeted Delivery of Anti-Cancer Drugs: Current Status and Future Prospects

(2010) Puneet Utreja et al.   Current Drug Delivery

Special feature of mixed phosphotriester derivatives of cytarabine

(2009) Marie-Hélène Gouy et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Advances in gene delivery through molecular design of cationic lipids

(2009) Santanu Bhattacharya et al.   CHEMICAL COMMUNICATIONS

Biodegradable polymeric nanoparticles based drug delivery systems

(2009) Avnesh Kumari et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Synthesis and evaluation of anti-tumor activities of N4 fatty acyl amino acid derivatives of 1-β-arabinofuranosylcytosine

(2009) Boyang Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues

(2009) Larryn W Peterson et al.   Expert Opinion on Drug Delivery

Ligand-based targeted therapy for cancer tissue

(2009) Manasi Das et al.   Expert Opinion on Drug Delivery

Emerging trends of nanomedicine - an overview

(2009) Selvarajan Sandhiya et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Niosomes in sustained and targeted drug delivery: some recent advances

(2009) Adnan Azeem et al.   JOURNAL OF DRUG TARGETING

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study

(2009) Oliver Weigert et al.   LEUKEMIA & LYMPHOMA

Intravenous administration of CP-4055 (ELACYT™) in patients with solid tumours. A phase I study

(2008) Svein Dueland et al.   ACTA ONCOLOGICA

CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines

(2008) Carlos M. Galmarini et al.   BRITISH JOURNAL OF HAEMATOLOGY

Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) Versus DHAP (Cytosine Arabinoside-Cisplatin-Dexamethasone) as Salvage Chemotherapy in Patients with Relapsed or Refractory Lymphoma

(2008) Hüseyin Abalı et al.   CANCER INVESTIGATION

Chitosan-Based Thermosensitive Hydrogel Containing Liposomes for Sustained Delivery of Cytarabine

(2008) Rohit Mulik et al.   DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments

(2008) Martin Benesch et al.   EXPERT OPINION ON PHARMACOTHERAPY

Recent advances in management of acute myeloid leukemia (AML)

(2008) Manasi Shah et al.   INDIAN JOURNAL OF PEDIATRICS

Pharmacokinetics of CPX-351 (Cytarabine/Daunorubicin HCl) Liposome injection in the mouse

(2008) William F. Bayne et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Anti proliferative activity of ELACYT™ (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells

(2008) David J. Adams et al.   LEUKEMIA & LYMPHOMA

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy

(2008) Paul Tardi et al.   LEUKEMIA RESEARCH

Synthesis, Transport and Pharmacokinetics of 5′-Amino Acid Ester Prodrugs of 1-β-d-Arabinofuranosylcytosine

(2008) Yongbing Sun et al.   MOLECULAR PHARMACEUTICS

Modern approaches to treating chronic myelogenous leukemia

(2008) Javier Pinilla-Ibarz et al.   Current Oncology Reports

Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting

(2007) Fujun Li et al.   JOURNAL OF PHARMACEUTICAL SCIENCES